Snapshot from Aug 23, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Evotec and Odyssey AI Drug Discovery...
Business R&D collaboration

Evotec and Odyssey AI Drug Discovery Collaboration

Analysis based on 9 articles · First reported Aug 06, 2026 · Last updated Aug 06, 2026

Sentiment
30
Attention
2
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The collaboration is expected to positively impact Evotec's stock as it validates its AI-enabled discovery platform and provides potential milestone revenue. Odyssey Therapeutics may benefit from accelerated drug discovery, enhancing its pipeline and attractiveness to investors.

Pharmaceuticals Biotechnology
Event Summary

Evotec and Odyssey Therapeutics, Inc. announced a strategic R&D collaboration on August 6, 2026, to discover potential new treatments for autoimmune and inflammatory diseases. Under the agreement, Odyssey will leverage Evotec's integrated data-driven discovery platform, advanced screening capabilities, and AI-enabled data science technologies to identify and validate differentiated small molecule drug candidates across multiple high-value disease targets. The collaboration combines Odyssey's expertise in autoimmune and inflammatory disease biology with Evotec's discovery infrastructure and proprietary compound libraries. Evotec is eligible to receive milestone payments based on the successful delivery of validated hit series for each target; detailed financials were not disclosed.

Key Actions
90 Evotec entered collaboration Odyssey Therapeutics
Entities Involved
stock
Evotec
Evotec is a key partner providing its AI-enabled discovery platform and screening capabilities. The collaboration could generate milestone payments and strengthen its position in AI-driven drug discovery.
Importance 100.0 Sentiment 40.0
priv
Odyssey Therapeutics
Odyssey leverages Evotec's platform to advance its discovery-stage programs in autoimmune and inflammatory diseases, potentially accelerating its pipeline and increasing its value.
Importance 90.0 Sentiment 35.0
per
Cord Dohrmann
As Chief Scientific Officer of Evotec, Cord Dohrmann is a spokesperson for the collaboration, highlighting its strategic importance.
Importance 20.0 Sentiment 0.0
per
Sarah Fakih
Sarah Fakih is the contact for investor relations and media, representing Evotec in communications regarding the collaboration.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.